Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model

Inflamed Intestinal Mucosa Features a Specific Epithelial Expression Pattern of Indoleamine 2,3-Dioxygenase

(2017) L. Ferdinande et al.   INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY

Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies

(2016) Senthamil R. Selvan et al.   CURRENT CANCER DRUG TARGETS

Chemotherapy and immunotherapy: mapping the road ahead

(2016) Alistair M Cook et al.   CURRENT OPINION IN IMMUNOLOGY

Atezolizumab: First Global Approval

(2016) Anthony Markham   DRUGS

Rationale for combining immunotherapy with chemotherapy

(2015) Angus G Dalgleish   Immunotherapy

In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia

(2015) Ilaria Iacobucci et al.   Journal of Hematology & Oncology

Effect of the association of 1-methyl-DL-tryptophan with paclitaxel on the expression of indoleamine 2,3-dioxygenase in cultured cancer cells from patients with breast cancer

(2015) Maria Letícia Baptista Salvadori et al.   MEDICAL ONCOLOGY

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Targeting the indoleamine 2,3-dioxygenase pathway in cancer

(2015) Yong Wha Moon et al.   Journal for ImmunoTherapy of Cancer

Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer

(2014) George C. Prendergast et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma

(2014) Minghui Li et al.   Journal for ImmunoTherapy of Cancer

Paclitaxel and immune system

(2009) Aqeel Javeed et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES